PAPER OF THE WEEK

On improvement in ejection fraction with Iron Chelation in Thalassemia Major and the risk of future heart failure.
J Cardiovasc Magn Reson. 2011 Sep 12;13(1):45.

Prof. Pennell and his group concluded that during treatment with iron chelators for cardiac siderosis, even small increases in LVEF in TM patients are associated with a significantly reduced risk of the development of heart failure. Thus the iron chelator induced improvements in LVEF of 2.6% to 3.1% that have been observed in randomized controlled trials, are associated with risk reductions of 25.5% to 46.4% for the development of heart failure over 12 months, which is clinically meaningful.